Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option

Gross Proceeds of Offering Total $110 Million

| Source: Revance Therapeutics, Inc

NEWARK, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its initial public offering of 6,900,000 shares of common stock at a public offering price of $16.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock at the same price to cover over-allotments. Gross proceeds from the sale of the shares is approximately $110 million. The net proceeds from the sale of the shares, after deducting the underwriters' discount and other estimated offering expenses will be approximately $98.7 million. 

Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering, with BMO Capital Markets acting as lead manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 5, 2014. A copy of the final prospectus relating to the offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email:

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. (Revance) is a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS®, that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.

Westwicke Partners
Ana Petrovic
(415) 513-1281